4519.T

Stock Details

4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 3,443.88￥. Average daily volumn in 3 months 2.24M. Market cap 6.20T

Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 3,773.00￥. Total volume : 1.09M. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)

Last Price

3,773.00￥

Change

-33.00

Volume

1.09M


Previous Close	3,806.00
Open	3,799.00
Day Range	3,758.00-3,840.00
Bid	3,772.00 x N/A
Ask	3,772.00 x N/A
Volume	1.09M
Average Volume	2.24M


Market Cap	6.2T
Beta	0.50
52 Week Range	3,191.00-3,930.00
Trailing P/E	19.63
Foward P/E	19.95
Dividend (Yield %)	2.10%
Ex-Dividend Date	2023-06-29

Financial Details

According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2022 were 1.26T an decrease( +0.1%) over the years 2021 revenue that were of 999.76B. In 2022 the company's total earnings were 374.43B while total earnings in 2021 were 303B( +23.43%).

Loading ...

Organization

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyr... oidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Market Cap:

6.20T

Revenue:

1.26T

Total Assets:

1.87T

Total Cash:

222.17B

News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical

Source from : Forbes - 18 days ago

Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals products. The Company develops drugs in the fields of cancer, infectious diseases, bone, blood, and circulatory systems.See details»

Taiwan FDA approves Chugai’s Actemra to treat Covid-19 in hospitalized adults

Source from : Pharmabiz - 1 month ago

Chugai Pharmaceutical Co., Ltd. announced that Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for ...See details»

Antibody cocktail 1st in Japan to be used before onset of COVID-19

Source from : 朝日新聞社 - 7 days ago

Chugai Pharmaceutical Co., which is in charge of the domestic sales of the drug, applied for approval in October for Ronapreve to be used to prevent COVID-19 symptoms from developing among ...See details»

Chugai seeks additional indication approval for Vabysmo for macular edema associated with RVO in Japan

Source from : Pharmabiz - 1 month ago

Chugai Pharmaceutical Co., Ltd. announced that it filed for additional application with the Ministry of Health, Labour and Welfare (MHLW) for anti-VEGF/anti-Ang-2 bispecific antibody Vabysmo ...See details»

Chugai Pharmaceutical Stock (OTC:CHGCF), Insider Trading Activity

Source from : Benzinga.com - 15 days ago

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades ...See details»

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with ...

Source from : newsroom.businesswire.com - 4 days ago

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated d ...See details»

Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Source from : newsroom.businesswire.com - 16 days ago

that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the avutometinib license agreement; that we or our other collaboration partners may fail to perform under our ...See details»

Chugai Mining Co Ltd

Source from : Morningstar - 1 month ago

Yes. 1491 has a forward dividend yield of 0.06%. See 1491’s full dividends and stock split history on the Dividend tab. Dividend yield allows investors, particularly those interested in dividend ...See details»

Dr Mandaviya interacts with Japanese pharma companies, JPMA in Tokyo

Source from : health.economictimes.indiatimes - 13 days ago

Daiichi Sankyo Co Ltd; Dr Osamu Okuda, Representative Director, President & CEO, Chugai Pharmaceutical Co Ltd; Mr Daikichiro Kobayashi, President, Meiji Seika Pharma Co Ltd; Hiroyoshi Tosa ...See details»

Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors

Source from : Stockhouse - 13 days ago

India recognized as global pharmaceutical hub, playing pivotal role in improving health outcomes worldwide: Mansukh Mandaviya

Source from : Big News Network.com - 14 days ago

Union Minister of Health and Family Welfare Mansukh Mandaviya here on Monday said India is recognized as a global pharmaceutical hub with its industry playing ...See details»

Chugai Pharmaceutical Co., Ltd.

Source from : Nikkei Asia - 6 month ago

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...See details»

Chugai Pharmaceutical Co. Ltd. ADR

Source from : Wall Street Journal - 3 days ago

1 Day CHGCY 0.30% DJIA 1.00% S&P 500 1.30% Health Care/Life Sciences 0.13% Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect ...See details»